Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387674128> ?p ?o ?g. }
Showing items 1 to 53 of
53
with 100 items per page.
- W4387674128 endingPage "1280" @default.
- W4387674128 startingPage "1275" @default.
- W4387674128 abstract "Objective: To evaluate the association of gender and age with the resistance shown to Imatinib in CML with evaluation of WBCC in different age groups. Study Design: Cross Sectional Analytical study. Setting: Islamic International Medical College, Riphah International University, Islamabad, Pakistan. Patients were enrolled from the CML clinic in Holy Family Hospital, Rawalpindi. Period: January 2019 to December 2021. Material & Methods: Sampling technique was non probability consecutive sampling. We included 75 newly diagnosed CML patients, who were taking Imatinib 400 mg. Blood samples of all these patients were analysed at the start of treatment and also after 3 months to determine the complete haematological response (CHR) and patients were labelled as resistant who failed to achieve complete haematological response at this stage according to the Leukemia Net guidelines. Results: Our study demonstrates that 54.7% of the patients were Imatinib responders while 45.3 % patients were Imatinib resistant. Patients who were labelled as responders have shown complete haematological remission at 3 months of treatment. (Platelet Count < 450 x 10 9/L - WBCC < 10 x 10 9/L - Differential without Immature Granulocytes (MC, PMC, MB) and With Less Than 5% Basophils - Non-Palpable Spleen) A chi square test of independence was performed to examine the relation between gender and response and between age groups and response. The relationship between age groups and response is significant with p value of 0.003. While the relationship when determined between gender and response, it was found to be non-significant with p value of 0.08. It was also found out that WBC count in responders is at lowest in second age group and also highest in second age group in case of resistant patients that is age between 31-40 years. Conclusion: Imatinib resistance is common while treating patients with chronic myeloid leukemia. There is significant association with the different age groups and non-significant association with the gender in terms of response to the treatment of Imatinib. It was also found that age also effects the WBC count with Imatinib though it was not significant." @default.
- W4387674128 created "2023-10-17" @default.
- W4387674128 creator A5007333996 @default.
- W4387674128 creator A5011076816 @default.
- W4387674128 creator A5016210979 @default.
- W4387674128 creator A5017179658 @default.
- W4387674128 creator A5031911512 @default.
- W4387674128 creator A5093070950 @default.
- W4387674128 date "2023-10-05" @default.
- W4387674128 modified "2023-10-17" @default.
- W4387674128 title "Imatinib resistance in CML and its association with age & gender." @default.
- W4387674128 doi "https://doi.org/10.29309/tpmj/2023.30.10.7588" @default.
- W4387674128 hasPublicationYear "2023" @default.
- W4387674128 type Work @default.
- W4387674128 citedByCount "0" @default.
- W4387674128 crossrefType "journal-article" @default.
- W4387674128 hasAuthorship W4387674128A5007333996 @default.
- W4387674128 hasAuthorship W4387674128A5011076816 @default.
- W4387674128 hasAuthorship W4387674128A5016210979 @default.
- W4387674128 hasAuthorship W4387674128A5017179658 @default.
- W4387674128 hasAuthorship W4387674128A5031911512 @default.
- W4387674128 hasAuthorship W4387674128A5093070950 @default.
- W4387674128 hasBestOaLocation W43876741281 @default.
- W4387674128 hasConcept C126322002 @default.
- W4387674128 hasConcept C2777583451 @default.
- W4387674128 hasConcept C2778729363 @default.
- W4387674128 hasConcept C71924100 @default.
- W4387674128 hasConcept C90924648 @default.
- W4387674128 hasConceptScore W4387674128C126322002 @default.
- W4387674128 hasConceptScore W4387674128C2777583451 @default.
- W4387674128 hasConceptScore W4387674128C2778729363 @default.
- W4387674128 hasConceptScore W4387674128C71924100 @default.
- W4387674128 hasConceptScore W4387674128C90924648 @default.
- W4387674128 hasIssue "10" @default.
- W4387674128 hasLocation W43876741281 @default.
- W4387674128 hasOpenAccess W4387674128 @default.
- W4387674128 hasPrimaryLocation W43876741281 @default.
- W4387674128 hasRelatedWork W1506200166 @default.
- W4387674128 hasRelatedWork W1995515455 @default.
- W4387674128 hasRelatedWork W2048182022 @default.
- W4387674128 hasRelatedWork W2080531066 @default.
- W4387674128 hasRelatedWork W2604872355 @default.
- W4387674128 hasRelatedWork W2748952813 @default.
- W4387674128 hasRelatedWork W2899084033 @default.
- W4387674128 hasRelatedWork W3031052312 @default.
- W4387674128 hasRelatedWork W3032375762 @default.
- W4387674128 hasRelatedWork W3108674512 @default.
- W4387674128 hasVolume "30" @default.
- W4387674128 isParatext "false" @default.
- W4387674128 isRetracted "false" @default.
- W4387674128 workType "article" @default.